Cytokinetics (CYTK) Long-Term Investments (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Long-Term Investments of $254.7 million for Q1 2026, up 69.04% year-over-year from $150.7 million in Q1 2025, and down 23.98% quarter-over-quarter from $335.0 million in Q4 2025.
Cytokinetics (CYTK) Long-Term Investments (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Long-Term Investments for 15 consecutive years, with $254.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments rose 69.04% year-over-year to $254.7 million; the TTM figure through Mar 2026 stood at $254.7 million (up 69.04% YoY), while the FY2025 annual figure was $335.0 million, up 130.98% from the prior year.
- Long-Term Investments eased to $254.7 million in Q1 2026 per CYTK's latest filing, from $335.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $335.0 million in Q4 2025 and bottomed at $10.7 million in Q2 2022.
- Historically, Long-Term Investments has averaged $131.1 million across 5 years, with a median of $77.1 million in 2022.
- Annual changes were most pronounced in 2022 — Long-Term Investments tumbled 85.52% — and 2024, when it jumped 1640.16%.
- Cytokinetics' Long-Term Investments stood at $46.7 million in 2022, then slipped by 13.22% to $40.5 million in 2023, then jumped by 257.86% to $145.1 million in 2024, then jumped by 130.98% to $335.0 million in 2025, then fell by 23.98% to $254.7 million in 2026.
- Business Quant data shows CYTK's Long-Term Investments at $254.7 million in Q1 2026, $335.0 million in Q4 2025, and $288.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 538.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 538.32 Mn |
| Mar 31, 2026 | 254.72 Mn |
| Dec 31, 2025 | 335.05 Mn |
| Sep 30, 2025 | 288.82 Mn |
| Jun 30, 2025 | 178.20 Mn |
| Mar 31, 2025 | 150.69 Mn |
| Dec 31, 2024 | 145.06 Mn |
| Sep 30, 2024 | 269.17 Mn |
| Jun 30, 2024 | 305.36 Mn |
| Mar 31, 2024 | 15.38 Mn |
| Dec 31, 2023 | 40.53 Mn |
| Sep 30, 2023 | 15.47 Mn |
| Jun 30, 2023 | 26.87 Mn |
| Mar 31, 2023 | 40.41 Mn |
| Dec 31, 2022 | 46.71 Mn |
| Sep 30, 2022 | 28.54 Mn |
| Jun 30, 2022 | 10.67 Mn |
| Mar 31, 2022 | 77.08 Mn |
| Dec 31, 2021 | 152.05 Mn |
| Sep 30, 2021 | 191.30 Mn |